207 related articles for article (PubMed ID: 17096154)
1. [Prevention of atherothrombotic incidents. CHARISMA Study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance].
Erdmann E
Internist (Berl); 2006 Dec; 47(12):1295-7. PubMed ID: 17096154
[No Abstract] [Full Text] [Related]
2. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
4. Identification of and management approaches for the high-risk patient.
Bhatt DL
Am J Cardiol; 2006 Dec; 98(12A):22Q-29Q. PubMed ID: 17169626
[TBL] [Abstract][Full Text] [Related]
5. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
Chen J; Shi C; Mahoney EM; Dunn ES; Rinfret S; Caro JJ; O'Brien J; El-Hadi W; Bhatt DL; Topol EJ; Cohen DJ
Can J Cardiol; 2011; 27(2):222-31. PubMed ID: 21459271
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
8. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
Hankey GJ; Johnston SC; Easton JD; Hacke W; Mas JL; Brennan D; Mak KH; Bhatt DL; Fox KA; Topol EJ;
Int J Stroke; 2011 Feb; 6(1):3-9. PubMed ID: 21205234
[TBL] [Abstract][Full Text] [Related]
9. Aspirin resistance or variable response or both?
Cheng X; Chen WH; Simon DI
Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
[TBL] [Abstract][Full Text] [Related]
10. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
11. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger JS; Bhatt DL; Steg PG; Steinhubl SR; Montalescot G; Shao M; Hacke W; Fox KA; Berger PB; Topol EJ; Lincoff AM
Am Heart J; 2011 Jul; 162(1):98-105.e1. PubMed ID: 21742095
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Helø OH; Madsen JK; Kastrup J
Ugeskr Laeger; 2004 Apr; 166(18):1659-62. PubMed ID: 15174400
[No Abstract] [Full Text] [Related]
13. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Mak KH; Bhatt DL; Shao M; Hankey GJ; Easton JD; Fox KA; Topol EJ
Am Heart J; 2009 Apr; 157(4):658-65. PubMed ID: 19332192
[TBL] [Abstract][Full Text] [Related]
14. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
15. [Primary and secondary prevention of stroke. Prevention is better than healing].
Stiefelhagen P
MMW Fortschr Med; 2004; 146 Suppl 1():12-7; quiz 18-9. PubMed ID: 15493414
[No Abstract] [Full Text] [Related]
16. Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
Alexandrov AV; Alagona P
Int J Stroke; 2008 Aug; 3(3):175-81. PubMed ID: 18705896
[TBL] [Abstract][Full Text] [Related]
17. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Spinler SA
Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
[TBL] [Abstract][Full Text] [Related]
19. [Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
Granitskiĭ NA
Kardiologiia; 2006; 46(5):73-5. PubMed ID: 16858363
[No Abstract] [Full Text] [Related]
20. [More modest use in secondary prevention, risky in primary prevention].
MMW Fortschr Med; 2006 Apr; 148(14):10-1. PubMed ID: 16669270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
